Acme United (ACU) Q1 2026 earnings review
Acquisitions Mask an Operating Expense Blowout
Acme United delivered a strong 14% top-line beat in Q1, breaking a year of sluggish growth. The newly acquired My Medic and German cutting tool lines fueled the surge. But the volume recovery completely bypassed the bottom line. Net income crashed 40% as operating expenses spiraled out of control. Tariff costs, quality assurance issues at the Med-Nap plant, and seasonal drag from My Medic devoured the profits. Management's defensive move to build $10M in inventory against Middle East risks has pushed net debt to its highest level in over a year. The revenue growth is real, but the current cost of that growth is too high.
🐂 Bull Case
Revenue jumped 14% (6% organic) with strong double-digit growth contributions across the U.S., Europe, and Canada. The M&A engine is driving tangible volume.
Despite severe tariff pressures and inflation, gross margins actually expanded to 39.7% from 39.0%, proving the company retains strong pricing power over its core products.
🐻 Bear Case
Operating income fell 28% as SG&A jumped by $3.5M. The company bought top-line growth through M&A but has momentarily lost control of its operating leverage.
Net debt spiked to $38.6M from $27.2M a year ago to fund the My Medic acquisition and a defensive $10M inventory build, reversing a year of disciplined deleveraging.
⚖️ Verdict: 🔴
Bearish. Buying 14% top-line growth at the expense of a 40% earnings collapse is a poor trade. Until management proves they can digest My Medic and normalize operating costs, the stock carries high execution risk.
Key Themes
M&A Drives Top-Line Acceleration
The $18.7M acquisition of My Medic (DTC first aid) and the German cutting tool line immediately accelerated sales, pushing U.S. revenue up 12% and Europe up 32% in USD. While My Medic is a seasonal drag in Q1, it positions Acme for a heavily profitable Q4 and opens a lucrative direct-to-consumer channel.
Operating Leverage Reversing
SG&A expenses spiraled, jumping from $15.5M in 25Q1 to $19.0M this quarter. This completely erased a $2.9M increase in gross profit, causing operating margins to compress from 5.3% to 3.3%. Management must prove this is a one-quarter integration blip rather than a structural cost increase.
The Tariff Lag Effect Contradicts the 2025 Narrative
Throughout 2025, management heavily promoted their domestic manufacturing as a flawless shield against 145% tariffs. Yet, earnings collapsed this quarter partly because 'tariff expenses were recognized... as the company sold inventory.' This data point contradicts their prior narrative; they didn't avoid the tariff pain, they merely delayed it by capitalizing it into inventory on the balance sheet.
Defensive Inventory Build (Macro Risk)
Citing the conflict in Iran and broader macroeconomic instability, management proactively ordered $10M of incremental inventory for Q2 and Q3 delivery. While prudent for supply chain security, this ties up massive amounts of working capital and forces the company to take on more floating-rate debt in a high-interest environment.
European E-commerce Revival
Europe flipped from a lagging segment to a massive growth engine, accelerating to 32% YoY growth in USD (19% in local currency). This was driven by a successful e-commerce pivot and the integration of the German sharpening tools acquisition, proving the international expansion strategy is gaining traction.
Spill Magic Automation & Consolidation
Technology and innovation investments continue to roll out. The company successfully moved into its new Tennessee Spill Magic facility, which is designed heavily around automation to offset rising healthcare and labor expenses. They also consolidated a Canadian site, pointing to structural margin improvements once integration costs fade.
Med-Nap Quality Assurance Misstep
Management recorded one-time expenses for 'enhanced quality assurance protocols at the Med-Nap facility.' This is a red flag. In 2025, Med-Nap was touted as running at record capacity to become a serious domestic medical supplier. QA issues suggest they scaled production faster than their quality control systems could handle.
Other KPIs
Stable/Accelerating. Up from 39.0% a year ago. This is a vital metric that proves the core product pricing power remains intact despite inflation. The profitability issue is entirely below the gross profit line.
Reversing. After a year of disciplined debt paydown (reaching $18.5M in 25Q4), net debt more than doubled in a single quarter to fund the $14.6M My Medic acquisition and defensive inventory buffers.
Guidance
Accelerating. Management is pulling forward $10M in inventory purchases to hedge against Middle East conflict risks. This will continue to pressure free cash flow and keep debt levels elevated through the summer.
Stable. Management guided that My Medic is a highly seasonal DTC business running at a loss in Q1 but will generate the vast majority of its profit in Q4. This implies near-term earnings deceleration, setting up a strong base effect for the end of the year.
Key Questions
Med-Nap QA Financial Impact
What was the exact dollar impact of the 'one-time' Med-Nap QA protocols on Q1 SG&A, and are the underlying production issues completely resolved?
Tariff Inventory Duration
You cited selling higher-tariff inventory this quarter. How many more quarters of this capitalized high-cost inventory remain on the balance sheet to drag on earnings?
Balance Sheet Strategy
With net debt spiking to $38.6M from $18.5M last quarter, are you pausing further M&A to digest My Medic and repair the balance sheet, or are you comfortable running at higher leverage?